ABVX Abivax Corp: Forward P/S Multiple
Investing in ABIVAX (ABVX) carries the critical risk of final drug trial failures and a rapid cash burn. The forward P/S trajectory visualizes market expectations, where the current level equals . While demand for intestinal inflammation therapies remains colossal, business success is dictated by regulatory verdicts rather than general economic trends or GDP dynamics.
Abivax Corp (ABVX) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
ABVX - Company Net Income|Future Profit ABIVAX|ABVX - Price to Earnings Ratio|Projected Price to Earnings Abivax SA|ABVX - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Abivax Corp|ABVX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Abivax|ABVX - Earnings per share for the trailing year|Quarterly EPS earnings growth abivax.com|ABVX - Earnings growth in current year|Net earnings per share growth forecast for next year ABIVAX
- sales revenue and business income indicators:
Fundamental company analysis:Abivax (ABVX)
The selection of defensive assets is based on identifying companies with fundamental growth potential, which at ABIVAX (ABVX) is driven by a concentration of leading immunologists and large-scale funding for breakthrough developments. By analyzing the forward price-to-sales multiple chart, an investor assesses the ratio of market demand to expected annual sales, where high line volatility signals the potential for excess profits alongside a significant risk of deep price corrections.
Competitor analysis for ABIVAX
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ADMA Bio - Forward P/S Multiple|PTGX - Forward P/S Multiple|IMVT: Forward P/S Multiple|KNSA (kiniksa.com) - Price-to-Projected Revenue Ratio|GRFS (Grifols) - Forward P/S Multiple|Adaptive Biotech (ADPT) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CLDX (Celldex)|Price-to-Projected Revenue Ratio AUPH (Aurinia Corp)|Forward P/S Multiple BCRX (BioCryst)|Forward P/S Multiple veratx.com VERA|DNTH: Forward Price-to-Revenue Multiple|PHVS (Pharvaris NV) - Market Cap to Projected Revenue|ABCL: Forward P/S Multiple|Tourmaline (TRML) - Forward P/S Multiple|PGEN (Precigen, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PHAR|Forward Price-to-Revenue Multiple NKTR (Nektar Therapeutics Inc.)|Price-to-Projected Revenue Ratio UPB (Upstream Bio, Inc.)|Zenas Biopharma, Inc. - Forward Price-to-Revenue Multiple|IMNM: Market Cap to Projected Revenue|GOSS - Price-to-Projected Revenue Ratio|Future Price to Revenue KALV|SEPN: Forward P/S Multiple|Pieris Pharma - Forward Price to Sales|SVRA (Savara Corp) - Forward P/S Multiple|Forward P/S Multiple Rigel Corp|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS (astriatx.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio enGene ENGN|RAPT - Forward Price-to-Revenue Multiple|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|tizianalifesciences.com - Forward Price to Sales|CABA (Cabaletta Bio) - Forward P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|Forward Price-to-Revenue Multiple Avalo Therapeutics Inc AVTX|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN - Forward Price-to-Revenue Multiple|CLYM: Forward Price-to-Revenue Multiple|ZURA - Forward P/S Multiple|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ADAG|IMA (ImageneBio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Shattuck Therapeutics STTK|Forward P/S Multiple EQ|Forward P/S Multiple connectbiopharm.com (CNTB)|Forward P/S Multiple IMUX (Immunic)|Atara Biotherapeutics, Inc. - Price-to-Projected Revenue Ratio|InflaRx GmbH - Forward P/S Multiple|Market Cap to Expected Sales Ratio x4pharma.com XFOR|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|CELU (Celularity) - Price-to-Projected Revenue Ratio|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Barinthus Biotherapeutics Corp|Forward Price-to-Revenue Multiple KZR (Kezar Life Sciences)|sabbiotherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|Q32 Bio Corp - Forward P/S Multiple|GOVX: Price-to-Projected Revenue Ratio|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|IBIO (ibioinc.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CARM|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|HCWB: Future Price to Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Forward Price to Sales AIM|Aditxt Corp - Forward P/S Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
